Boston Scientific Corp has delayed commercialization of its troubled Lotus transcatheter aortic valve business citing ongoing performance issues with the mechanical delivery system. This is the third time the company has delayed timing of Lotus, prompting the belief the TAVR system's days are numbered.
Boston Scientific initiated a worldwide voluntary removal of the LOTUS and LOTUS Edge Aortic Valve Systems in February following reports...